Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Exelixis Q3 2026 Results: Net Income $218M, Up 12.7% YoY

Exelixis reported total revenues of $1.90 billion for the first nine months of 2026, driven primarily by $1.73 billion in net product revenues. Net income for the same period rose to $640.6 million, up from $538.0 million in 2025, despite significant common stock repurchases totaling over $1.0 billion.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue658.7597.8
Net income218.1193.6
EPS (diluted, $ a share)$0.85$0.69

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+12.7%
Revenue, year on year+10.2%
Operating margin40.8%
Source

10-Q filed with the SEC, NASDAQ: EXEL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Exelixis, Inc.: key numbers

Share price
$67.10Close, Nov 16
Market cap
$16.4B
Shares outstanding
244.01MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Exelixis, Inc.

All →
4:10 PM ET 8-K
Financial Results

Exelixis Financial Results

Exelixis reported third quarter 2026 total revenues of $658.7 million, driven by $604.9 million in net product revenues from the cabozantinib franchise. The company achieved GAAP net income of $218.1 million and is focused on advancing its zanzalintinib development program and clinical pipeline.

Term
Q3 2026

“Exelixis continued to execute across all of our key priorities in the third quarter, driving the cabozantinib franchise forward while preparing for zanzalintinib as our next potential franchise opportunity. The zanzalintinib development program gained further momentum as the organization focused on trial initiations, enrollment progress for ongoing studies and in-depth planning for the next wave of new pivotal trials.”

Michael M. Morrissey, Ph.D., President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.